

SYSTEMATIC REVIEW

Open Access



Antibiotic resistance in hospital wastewater in West Africa: a systematic review and meta-analysis

Prince Hotor^{1*}, Fleischer C. N. Kotey¹ and Eric S. Donkor^{1*}

Abstract

Background The occurrence of antibiotic-resistant bacteria (ARB) has become a global menace and therefore increases morbidity, mortality and healthcare costs. Globally, hospital wastewater (HWW) has been identified as a significant source of antibiotic-resistant elements.

Objectives This review aims to systematically review and to perform meta-analyses from evidence on antibiotic resistance studies in HWW in West Africa.

Methods The review was conducted in compliance with PRISMA and included studies published between 1990 and 2024 in West Africa from the Scopus, PubMed, and Web of Science databases. Eligible studies that characterized resistant bacteria, genes, or antibiotic residues in HWW were included. Meta-analyses for resistant bacteria and genes as well risk of bias using the Newcastle–Ottawa scale were conducted.

Results Out of 23 studies reviewed, resistant bacteria were reported in 39% (*E. coli*), 26% (*K. pneumoniae*), and 17% (*P. aeruginosa*), while 17 studies reported ARGs, with *bla*TEM (29%), *bla*OXA-48 (18%), *bla*SHV (18%), and *mecA* (18%) being the most common. Only 4% and 9% of studies focused on toxin genes and antibiotic residues, respectively. Meta-analysis showed pooled prevalence rates for resistant bacteria: *E. coli* 42.6% (95% CI: 26.7%–60.3%) and *K. pneumoniae* 32.1% (95% CI: 28.8%–36.5%), and ARGs: *bla*TEM 76.0% (95% CI = 64.6%–84.6%) and *bla*SHV 59.3% (95% CI = 19.5%–89.8%).

Conclusion This systematic review highlights significant findings of high levels of ARGs and ARBs of public health concern in HWW in West Africa. This highlights the need to improve upon the monitoring of antibiotic resistance and treatment of HWW in West Africa.

Keywords Antibiotic resistance, Hospital wastewater, Antibiotic-resistant bacteria, Antibiotic resistance genes, Antibiotic residues, West Africa, Wastewater treatment, Horizontal gene transfer

Introduction

The rapid global rise in antibiotic resistance (AR) is significantly diminishing the effectiveness of many antibiotics, leading to higher mortality and morbidity rates, prolonged hospitalizations, and escalating healthcare costs [1]. According to Global Research on Antimicrobial Resistance (GRAM), one million people die each year from 1990 to 2021, attributed to AR [2]. It has been estimated that the burden of deaths by antibiotic resistance

*Correspondence:

Prince Hotor
photor001@st.ug.edu.gh
Eric S. Donkor
esampane-donkor@ug.edu.gh

¹ Department of Medical Microbiology, University of Ghana Medical School, 00233 Accra, Ghana



© The Author(s) 2025. **Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/>.

may increase to 10 million each year by 2050, if action is not taken now [3]. The available evidence indicates that the attributable cost of resistant infection ranges from -US\$2,371.4 to +US\$29,289.1 (adjusted for 2020 price) per patient episode; the mean excess length of stay (LoS) is 7.4 days (95% CI: 3.4–11.4), the odds ratios of mortality for resistant infection is 1.844 (95% CI: 1.187–2.865) and readmission is 1.492 (95% CI: 1.231–1.807) [4]. According to the systematic review and meta-analyses [4], the baseline for estimation of these cost were between resistant and their non-resistant counterpart. For example, in some studies, the cost of treating methicillin-resistant *Staphylococcus aureus* (MRSA) related illness is higher than non-resistant methicillin-susceptible *Staphylococcus aureus* (MSSA). Additionally, the early mortality of a some resistant-related illnesses in hospitals also accounts for low cost in treatment as compared to susceptible ones. Finally, the method of treatment and hospital facilities used in the treatment process varies from different health facility and could also affect the cost variation between susceptible and resistant-related illnesses [5]. In low- and middle-income regions such as West Africa, an estimated 1.85 million deaths in 2019 were associated (deaths where infection was a contributing factor) with infections, 524,000 were associated (resistance complicated treatment but may not have been the primary cause of death) with antibiotic resistance, and 125,000 were directly attributable (antibiotic resistance was the direct cause of death) to resistant infections [6]. Several factors have been implicated as contributory factors to the phenomenon, some of which include inappropriate use of antibiotics in human health and agriculture, genetic mutations, poor infection control in healthcare facilities, poor hygiene, and lapses in antimicrobial stewardship such as inconsistent implementation and enforcement [7–9]. Additionally, gaps in antibiotic resistance research, including limited surveillance data and insufficient development of novel antibiotics, further exacerbate the issue. Thus, addressing antibiotic-resistance from the “One Health” perspective, which considers the spread of antibiotic-resistant bacteria (ARB), antibiotic resistance genes (ARGs), and antibiotic residues (ARes) between and within humans, animals, and the environment, has been touted as an efficient approach to resolving the antibiotic resistance crisis [10]. In the environment, wastewater from municipalities, hospitals, treatment plants, and aquatic environments serve as reservoirs for large amounts of ARGs (including transposons), ARB, and ARes, as well as other chemical agents [11, 12]. These ecosystem components, along with physiochemical parameters such as temperature, pH, and redox conditions, create environments that facilitate the spread of antibiotic resistance. Factors such as horizontal gene

transfer (HGT), selective pressure from microbial competition, and prolonged exposure to antibiotic residues further drive this process [13].

Globally, the hospital environment, where nosocomial infections are rife, is a hotspot for the transfer of antibiotic resistance properties between bacteria species [14]. Notably, hospital wastewater (HWW) across the globe is reported to contain ARGs, ARes, and a combination of ARB and non-ARB. This provides an environment for exchanging resistance genes and selectively pressuring bacteria, exacerbating the occurrence of resistant species [15]. Even though wastewater effluents from various hospital units are treated [16], most of these treatments are either ineffective or inefficient, leading to the transfer of these antibiotic-resistant components to aquatic ecosystems, such as rivers, streams and drainage systems, potentially endangering public health [17]. In West Africa, where the antibiotic resistance crisis is at its highest [18], HWW is a major source of antibiotic resistance transfer or infection in most West African countries [19]; thus, management should take care to prevent the spread of antibiotic resistant and antibiotic-resistant-related infections [20]. Additionally, research into hospital waste-related antibiotic-resistant, especially in the context of ARGs, ARB, antibiotic resistant elements, and ARes, is limited [21]. Similarly, appraisals of the effectiveness of HWW treatments in reducing the potential for infection and antibiotic resistance transfer from HWW are sparse [21].

Existing systematic reviews on antibiotic resistance (AR) in hospital wastewater (HWW) primarily focus on global or Africa-wide data, often limited to bacteria and/or resistance genes [21, 22]. Additionally, reviews on antibiotic residues are either systematic review protocols [23] or scoping reviews that explore their effects on adjacent water bodies (e.g., rivers, streams) [24]. However, AR in HWW results from complex interactions among antibiotic-resistant bacteria (ARBs), antibiotic resistance genes (ARGs), antibiotic residues (ARes), and physiochemical parameters. In West Africa, there is a lack of systematic reviews and meta-analyses that comprehensively examine AR in HWW, including ARBs, ARGs, and ARes—critical data needed to assess the state of AR research in HWW. This review aims to bridge this gap by providing a systematic overview and meta-analysis of antibiotic resistance in West African HWW. It will offer insights into the prevalence of AR in the region, evaluate the effectiveness of HWW treatment strategies, and highlight the need for expanded research. Ultimately, the findings will help inform policies and strategies for the effective treatment and management of HWW in West Africa.

Materials and methods

Search strategy

A systematic review without meta-analysis was conducted using the PRISMA guideline for reporting systematic reviews [25]. Individual studies spanning 1990–2024 were resourced from three databases (Scopus, PubMed, and Web of Science) on the 25 th of July 2024 and re-searched again on the 30 th of August 2024. The search queries together with the connectors used were “Antibiotic resistance bacteria” OR “Antibiotic resistance genes”, OR “Antibiotic residues” AND “Hospital wastewater”, AND West Africa countries (‘Benin’, OR ‘Burkina Faso’, OR ‘Cape Verde’, OR ‘Côte d’Ivoire’, OR ‘Gambia’, OR ‘Ghana’, OR ‘Guinea’, OR ‘Guinea-Bissau’, OR ‘Liberia’, OR ‘Mali’, OR ‘Niger’, OR ‘Nigeria’, OR ‘Senegal’, OR ‘Sierra Leone’, OR ‘Togo’. The comprehensive details of the search strategy is provided in Table S31.

Study selection

To ensure that all the studies and records collected met the criteria essential for this systematic review, several inclusion and exclusion criteria were followed. For the inclusions, all original research work that was conducted in West Africa, with studies on either ARGs, ARB, or ARes in HWW, were selected. Additionally, studies whose full texts were accessible were the only ones used. Conversely, systematic and literature reviews, studies outside West Africa, studies that did not include HWW, and studies with no access to full-length articles were excluded. Additionally, studies that were not published in the English language were also excluded.

Quality assessment

This study was based on previously published research articles with observational evidence. To maintain the quality of the review, all duplicate articles were meticulously identified and removed. The abstracts of the selected articles were carefully examined and verified prior to analysis to ensure that only relevant and high-quality information was included. The quality assessment of the chosen articles was independently conducted by the authors.

Data extraction and analysis

Data was extracted from individual studies via a customized form, and a database was created specifically for this review in Microsoft Excel 2016. Additionally, the map was designed via the Python language. The form captured details such as the authors’ names; study title; year of publication; country of study; hospital and unit where samples were collected; keywords; sampling methods; identified ARGs, ARB, and ARes; and identification methods used. For studies reporting findings in

percentages, these were converted to whole numbers to ensure consistency across the data. To calculate pooled prevalence rates and the corresponding 95% confidence intervals (CIs), meta-analysis was done using Comprehensive meta-analysis software Version 3.3.070. Utilizing statistical techniques including the tau-squared test and I-squared statistic, the heterogeneity of the included papers was evaluated. A random-effects model was employed for the meta-analysis if significant heterogeneity was seen; otherwise, a fixed-effects model was utilized. Publication bias was assessed visually using funnel plots to detect asymmetry that could arise from non-publication of small or non-significant studies. This assessment of bias was only conducted for factors with three or more studies.

Evaluation of bias

Possible biases in individual studies were assessed by means of the Newcastle Ottawa Scale, which is used to assess non-randomized studies [26]. For cross-sectional studies, the NOS assesses selection, comparability, and outcome criteria. Each study was rated out of four stars for the choice of study populations, two stars for comparability of groups, and three stars for the verification of the chosen outcome of interest. The samples with six stars or above were classified as having low-risk biases, those with four to five stars as having moderate-risk bias, and those with below four stars as having high-risk biases. In using NOS, two individuals (P.H and E.S.D) independently assessed the individual studies, and disagreement in the assigned number of stars was discussed and reviewed. Details of quality assessment are shown in Supplementary Table S4.

Results

Search results

The total number of articles (4,016) from the various databases (Scopus, PubMed, and Web of Science) collected from using all the search queries were thoroughly screened via Mendeley (Version 1.19.8) by Elsevier to adequately identify and remove duplicates (2,606 articles removed), after which the remaining records were transferred to the free version of the Rayyan website (a systematic review and meta-analysis online website) [25]. The Rayyan system was used to further identify and resolve duplicates (347 articles) that were not picked up by Mendeley via a comparison percentage (89–100%) interval. After this, the remaining 1,063 articles were screened via Rayyan, and systematic reviews and other reviews (91 articles) were excluded. Additionally, 942 articles that were not conducted in West Africa were excluded. Four of the remaining 30 articles were subsequently removed because the full articles could not be assessed (after




Fig. 1 Schematic representation of the search strategy for records and articles using the PRISMA criteria

searching through alternative websites such as ResearchGate). The titles and abstracts of the remaining 26 articles were further screened to ensure that they met the inclusion and exclusion criteria. One article was removed because it focused more on the treatment of HWW to remove microorganisms than on the identification of resistance in HWW. Finally, out of the 25 articles, one was on hospital-unrelated wastewater, and one study was an announcement. The remaining 23 articles were used for the systematic review. A schematic diagram of the study selection process is shown in Fig. 1.

Study characteristics

Figure 2 displays the West African map showing the number of studies conducted in the individual West African countries. Among the 23 studies used in this review, 13 were conducted in Nigeria [27–40], followed by Ghana (n = 4) [39, 41–44], Burkina Faso (n = 5) [45–49], and Benin (n = 1) [45], and within 2008–2024, a timeframe of 16 years. Among the 58 hospitals in West Africa where antimicrobial resistance in HWW was conducted, 17 are medical and health centres [32–34, 37, 47,–50], eight are university hospitals [27, 28, 31, 38, 46, 47], and five are teaching hospitals [34, 39, 41, 43, 44, 48].




Fig. 2 West African countries that have several studies on antimicrobial resistance in HWW

About 26% (6/23) of the studies were conducted in teaching hospitals [34, 37, 39, 41, 43, 48], 35% (8/23) in university hospitals and university medical centres [27, 28, 30, 34, 46, 47], and 13% (3/23) in regional hospitals [33, 42, 48]. In 30% of the studies (7/23), the units from where samples were taken were not specified. In contrast, 9% (2/23) were from HWW collection units [32, 38], 13% (3/23) from HWWTP [27, 35, 39], 13% (3/23) from sewers and septic tanks [42, 45, 48], and the remaining units were laboratories [30, 34, 37, 47], sick bay [38], diagnostic centres [33], hospital washrooms [37], and maternity and child health units [43].

In terms of sampling approach, 26% (6/23) of the studies sampled biweekly [34, 38], and weekly [32, 37, 40], and [35], while in one (representing 4% of the studies) [38], sampling was done monthly. For some (3/23, 13%), the sampling was done daily, with some being consecutive days [28] while others selected days (Mondays and Thursdays) [43], and another twice daily [31]. On the

other hand, there were some studies (3/23) (13%) in which samples were collected seasonally [27, 45], and [41]. In some studies (2/23) (9%), sampling was done at intervals of minutes [33] and [43] while about 35% of the remaining studies did not indicate sampling times. Details of the sampling technique and time is in Table S2.

In terms of sampling style, (2/23) 9% of the studies sampled randomly [47], while the remaining studies did not indicate their sampling style. Additionally, all studies with samples ≤ 50 HWW (6/23) were about 26% [31, 36, 41, 49], while about (5/23) 22% of the studies recorded to have taken over 50 samples [32, 43, 45, 47, 48].

Only (1/23, 4%) of the studies assessed the physico-chemical properties of HWW. The measured parameters included pH, dissolved oxygen (DO), chemical oxygen demand (COD), and biological oxygen demand (BOD). pH ranged from 5.31 ± 0.62 (postnatal ward) to 8.93 ± 0.74 (children's ward). DO levels varied from 2.01 ± 0.02 mg/L (UNIMED Laundry) to 8.31 ± 0.11 mg/L (UNIMED

Water Source). COD values were between 5.11 ± 0.05 mg/L (UNIMED Water Source) and 931.44 ± 5.06 mg/L (UNIMED Laundry), while BOD ranged from 3.68 ± 0.07 mg/L (FUTA Water Source) to 11.73 ± 0.93 mg/L (UNIMED Laundry). In some cases, the BOD/COD ratio was below 0.03, suggesting low biodegradability of organic matter.

In order to identify bacteria and discover antibiotic resistance genes (ARGs), the included research used a combination of culture-based, phenotypic, and molecular approaches. Every study (23/23, 100%) isolated bacterium using culture-based methods, however the culture media and incubation conditions varied. In 9 out of 23 research, MacConkey Agar was the most commonly utilised medium. It was incubated for 18 to 24 h at 35 ± 2 °C. For the primary purpose of isolating *Staphylococcus* species, mannitol salt agar was placed on 7/23, 30%, and incubated for 24 h at 37 °C. In (3/23, 13%) of the investigations, chromogenic coliform agar was used, which is normally incubated for 24 h at 37 °C.

Additionally, specific culture media were used, such as *Clostridium welchii* agar supplemented with kanamycin in (1/23, 4%), which was incubated anaerobically for three days at 37 °C. For coliform differentiation, Eosin Methylene Blue (EMB) agar was utilised in (6/23, 26%) and incubated for 24 h at 37 °C. To identify haemolytic bacteria, blood agar was used in (5/23, 22%) and incubated at 37 °C for 24 h under 5% CO₂ conditions. Additional culture conditions included the use of Plate Count Agar for general bacterial enumeration in (1/23, 4%), incubated at 37 °C for 24 h, and CHROMagar for multidrug-resistant strains in (2/23, 9%), incubated at 37 °C for 24 to 48 h.

Bacterial identification was conducted using various biochemical and molecular techniques. Biochemical testing was performed in (5/23, 22%) of studies using API 20E and API 20 NE kits for Enterobacteriaceae and non-fermenting Gram-negative bacteria, respectively. MALDI-TOF-MS was used in (4/23, 17%), while Gram staining and biochemical tests were performed in (6/23, 26%) for preliminary bacterial characterization. Some studies further confirmed bacterial species using the API 20E identification system (3/23, 13%) and the API 20 NE system (2/23, 9%). The VITEK 2 automated system was used in (1/23, 4%) for rapid bacterial identification. Molecular methods were also employed for bacterial identification in (11/23, 48%) of studies. Conventional PCR targeting the 16S rRNA gene was conducted in (5/11, 45%), while Sanger sequencing was used in (3/11, 27%) for confirming bacterial species. Whole Genome Sequencing (WGS) was applied in (3/11, 27%) for complete bacterial genome characterization, enabling species-level identification and resistance gene detection.

In most studies antibiotic susceptibility testing (AST) was carried out and the Kirby-Bauer disk diffusion method was used by (16/23, 70%). Among these (14/16, 87%) followed CLSI guidelines while (2/16, 13%) was in accordance with EUCAST protocols. AST was performed on (11/16, 69%) of studies at 35 ± 2 °C for 18–24 h and (5/16, 31%) at 37 °C for 18–24 h. Minimum inhibitory concentration (MIC) values were determined by the Broth Microdilution (BMD) method in (2/23, 9%) of the studies. Moreover, the Double Disc Synergy Test (DDST) was used in (4/23, 17%) to eye for Extended Spectrum Beta-Lactamase (ESBL) producers of bacteria.

Studies were widely using molecular techniques to confirm ARGs positivity; in (18/23, 78%) studies, the positivity was confirmed by the use of PCR methods. Both conventional PCR and multiplex PCR were similarly used, in (9/18, 50%) of cases. In (13/23, 57%) of the studies, gel electrophoresis was used to visualize the gene. In (5/23, 22%), Sanger sequencing was used and in (3/23, 13%) WGS was applied. For high precision gene quantification, high precision gene quantification was done by quantitative PCR (2/23, 9%) and droplet digital PCR (ddPCR, 1/23, 4%). Table 1 provides a detailed information on the various culturing, gene and bacterial identification, and AST methods.

Risk of bias

The risk of bias was assessed to ascertain the quality of the studies used for the review. All the 23 studies were used for this risk of bias. The assessment was modified as done by Hassoun-Kheir et al. [52]. The overall assessment can be judged as good. Out of the 23 studies, 19 (82.6%) was judged to have low-risk, and 4 (17%) a moderate risk. When it comes to the area of selection, only (2/3) studies had (3-star rating) [45, 53], this due to the comparison made through samples taken from different countries. In the area of comparability none of the studies had a mark, because no confounding variables was controlled. Finally, in the area of outcome, (22/23) of studies got (3-star) except [28] that had (2/3), due non-assessment of bacteria/gene and co-factors.

Antibiotic susceptibility result

Out of the 23 studies included in this review, 25 antibiotics (for AST analyses) appearing in three or more papers were analyzed. The prevalence for these antibiotics were 52.17% each for ciprofloxacin and gentamicin, 47.83% for ceftazidime, 30.43% each for cefotaxime and imipenem, 26.09% each for tetracycline, ampicillin, cefepime, and ceftriaxone, 21.74% each for ertapenem, amoxicillin-clavulanate, amikacin, and erythromycin, 17.39% each for meropenem, ceftoxitin, azithromycin, and cefuroxime, and 13.04% each for vancomycin, cefpodoxime,

Table 1 Summary of culturing, gene and bacterial identification, and AST methods

Summary of culture-based technique	Gene identification technique	Bacteria identification	AST method	Reference
thioglycolate medium at 37 °C for 3 days; Clostridium welchii agar plates + kanamycin at 37 °C under anaerobic conditions and sheep blood agar	Multiplex PCR of genes	16S rRNA Sanger sequencing	EUCAST 2021 guidelines using the Kirby Buer disk diffusion, on Fastidious Anaerobe Agar plates containing 5% horse blood	[42]
Mannitol Salt agar	PCR amplification of genes and gel electrophoresis	Biochemical test	CLSI, Kirby Buer disk diffusion Methods on Mueller Hinton agar, 35 ± 2 °C for 18–24 h	[50]
MacConkey agar + Cefotaxime, at 35 ± 3 °C for 24 h	PCR amplification of genes and gel electrophoresis	API 20E (BioMérieux SA, Lyon, France) system	Using recommendations from CA-SFM 2019 with the Kirby Buer disk diffusion method on Mueller Hinton Agar	[46]
(eosin methylene blue (EMB), centrimide, MacConkey, salmonella-shigella, and nutritional agar),	PCR amplification of gene and gel electrophoresis	N/A	CLSI, Kirby Buer disk diffusion Methods on Mueller Hinton agar, 35 ± 2 °C for 18–24 h	[32]
nutrient agar medium + sulfadiazine, a sulfonamide, 35 ± 2 °C for 24 h	PCR amplification of genes and gel electrophoresis	Gram staining and biochemical test	CLSI, Kirby Buer disk diffusion Methods on Mueller Hinton agar, 35 ± 2 °C for 18–24 h	[36]
Chromocult® Coliform Agar, Plate count Agar Tri-phenyl Tetrazolium Chloride (TTC) agar supplemented with ceftriaxone, 37 °C for 24 h. Conformation with Eosin Methylene Blue (EMB) agar,	Multiplex PCR of genes and sequencing	MALDI-TOF-MS and API 20E gallery (bioMérieux, Marcy-l’Étoile France)	Using recommendations from CA-SFM 2021 and EUCAST 2021 guidelines using the Kirby Buer disk diffusion	[47]
enriched within Bacto tryptic soy broth, Mannitol salt agar for 33°C for 24 h. MRSA CHROMagar base at 37 °C for 48 h	PCR amplification of genes and gel electrophoresis	16S rRNA PCR and sanger sequencing	CLSI, Kirby Buer disk diffusion Methods on Mueller Hinton agar, 37°C 18–24 h	[40]
thiosulphate citrate bile salts sucrose (TCBS) at 37°C for 48 h	N/A	PCR and sanger sequencing	CLSI, Kirby Buer disk diffusion Methods on Mueller Hinton agar, 37°C 18–24 h	[29]
Mannitol Salt Agar (MSA) for isolating Staphylococcus aureus, Eosin Methylene Blue (EMB) for Escherichia coli, and MacConkey agar as a selective agent for Enterobacteriaceae at 37°C for 24 h	Conventional PCR of the beta-lactamase gene and sequencing	Gram staining and biochemical test. 16S rRNA PCR and sanger sequencing	CLSI, Kirby Buer disk diffusion Methods on Mueller Hinton agar, 37°C 18–24 h	[51]
Mesophilic aerobic flora (FAMT) was carried out using ISO 7218 (2007) standard procedures. Total	N/A	API 20 NE kit (bioMérieux®, France) for Pseudomonas and API 20E kit (bioMérieux®, France)	Using recommendations from CA-SFM 2019	[49]
N/A	N/A	N/A	N/A	[28]
N/A	Metagenomics and bioinformatic analysis	Metagenomics and bioinformatic analysis	N/A	[45]
MacConkey agar 35 ± 2 °C for 18–24 h. double disc synergy test (DDST) for detecting ESBL and	Real Time PCR (Multiplex PCR)	API 20E identification kit (API System, France)	CLSI, Kirby Buer disk diffusion Methods on Mueller Hinton agar, 35 ± 2 °C for 18–24 h	[37]
MacConkey and blood agar for Enterobacteriaceae and Streptococcus, respectively for 37 °C for 24–48 h	N/A	Gram staining and biochemical test	CLSI, Kirby Buer disk diffusion Methods on Mueller Hinton agar, 35 ± 2 °C for 18–24 h	[33]

Table 1 (continued)

Summary of culture-based technique	Gene identification technique	Bacteria identification	AST method	Reference
MacConkey agar plates, with and without gentamicin, imipenem, amikacin,	Commercial PCR of RTmase and carbapenems genes, and whole genome sequencing qPCR	MALDI-TOF-MS	EUCAST and CLSI guidelines, Broth Microdilution (BMD) method	[44]
CHROMagar E. coli (CHROMagar, France) amended with cefotaxime, 35 ± 2 °C overnight. Confirmation of ESBL using double disc synergy test (DDST)		API20E (bioMérieux, Inc., Durham, NC) and Enterotube II (Becton, Dickinson, and Company) identification systems	CLSI, Kirby Buer disk diffusion Methods on Mueller Hinton agar, 35 ± 2 °C for 18–24 h	[35]
CHROMagar Acinetobacter media with CHROMagar MDR Supplement CR102 (CHROMagar, 37 °C for 24 h, after which was supplemented with cefotaxime for resistant <i>A. baumannii</i>	Whole genome sequencing and bioinformatic analysis	VITEK two automated system	VITEK two automated system using the CLSI guidelines using the AMR testing N281 cards	[27]
ESBL selective ChromAgar at 35°C for 24 h, for positive control Cystine Lactose Electrolyte Deficient (CLED) agar was used. Purification on Eosin Methylene blue. Confirmation test using double disc synergy test (DDST) using Mueller Hinton agar. AmpC-lactamase production using Mueller Hinton agar. immuno- nonchromatographic test for testing carbapenems	N/A	API20E system (Biomérieux, Marcy-l'Étoile, France)	CLSI, Kirby Buer disk diffusion Methods on Mueller Hinton agar, 37°C 18–24 h	[48]
Direct streaking samples on 5% sheep blood and chocolate agar at 37 °C for 24 h, under 5% CO ₂ . Also, Mannitol salt agar and MacConkey agar for 24 h, at 37°C. Confirmation using double-disc synergy test (DDST) for ESBL using Mueller Hinton agar	N/A	Gram stain, biochemical test, and MALDI-TOF-MS	CLSI, Kirby Buer disk diffusion Methods on Mueller Hinton agar, 37°C 18–24 h	[43]
Standard culturing on Chromogenic coliform agar at 37°C for 24 h, after subsequent culturing on eosin methylene blue for confirmation. Further confirmation using double-disc synergy test (DDST) for ESBL using Mueller Hinton agar	Whole genome sequencing and bioinformatic analysis	Gram stain and MALDI-TOF-MS	Using CLSI Kirby Buer disk diffusion method on Mueller Hinton agar, 37°C 18–24 h	[41]
N/A	droplet digital polymerase chain reaction (ddPCR) of TB resistant gene from water	N/A	N/A	[39]
Membrane filtration method on nutrient agar, and selective media (Salmonella Shigella agar, Eosin Methylene Blue agar, MacConkey agar and Mannitol Salt agar) at 37°C for 24 h	Conventional PCR of <i>mecA</i> from DNA and visualizing using gel	Sequencing of 16S rRNA gene	Using CLSI guidelines, the Kirby Buer disk diffusion method, with Muller Hinton agar, 37°C 18–24 h	[31]

chloramphenicol, oxacillin, nalidixic acid, norfloxacin, Fosfomycin, and trimethoprim-sulfamethoxazole. Out of studies reviewed, the resistance rate of isolates to ciprofloxacin was in a range between (5.6–100.0%), gentamicin (8.0–100.0%), ceftazidime (12.5–100.0%), cefotaxime (10.0–100.0%), imipenem (4.0–100.0%), tetracycline (25.0–100.0%), ampicillin (63.2–100%), cefepime (12.5–100%), ceftriaxone (14.0–100.0%), ertapenem (3.4–100.0%), amoxicillin-clavulanate (20.0–100.0%), amikacin (2.25–21.10%), erythromycin (12.5–91.3%), meropenem (8.19–100.0%), ceftiofloxacin (12.36–100.00%), azithromycin (32.00–68.69%), and cefuroxime (5.6–100.0%) (Table S2).

Antibiotic resistance bacteria, genes, and residues

Out of the 23 reviewed papers, (9/23) 39% reported the isolation or identification of *E. coli* followed by *K. pneumoniae* (6/23) 26%, and *P. aeruginosa* (4/23) 17%. *Enterobacter cloacae* were identified in (3/23) 13% reviewed, with (2/3) 9% of papers indicating the identification of *S. epidermis*, *S. aureus*, *Citrobacter spp.*, and *Bacillus cereus*. The remainder (1/23) 4% includes *Shigella spp.*, *Serratia spp.*, *Salmonella spp.*, *Proteus spp.*, and *R. rettgeri*.

Similarly, (6/23) 26% of the reviewed papers did not record the isolation or identification of ARGs. From the remainder (17/23), (11/17) 65% were beta-lactamase genes, (3/17) 17% each were methicillin resistance and aminoglycoside resistance genes, and (2/17) 12% each were tetracycline resistance and sulphonamide resistance genes. Other classes of ARGs reported (1/17) 6% each includes, colistin, macrolide, trimethoprim, mycobacterial, quinolone, chloramphenicol, disinfectant, and others (Unknown classifications) (Table S3). Of these, only (1/23) 4% reported the identification of ARGs directly from the HWW [45].

From these reported ARGs, three of them: *blaTEM* (5/17) 29%, *blaOXA-48* (3/17) 18%, *blaSHV* (3/17) 18%, and *mecA* (3/17) 18% were reported by ≥ 3 reviewed papers. The others reported by two reviewed papers include *blaCMY-1*, *blaCTX-M-1*, *blaCTX-M-15*, *blaCTX-M-25*, *blaCTX-M-8*, *blaCTX-M-9*, *blaDIM-1*, *blaIMP*, *blaNDM*, *blaOXA-1*, *blaOXA-58*, *blaVIM*, *su1*, *tetA*, and *tetB* (Table S3). Additionally, only one study [42] reported on the isolation and identification of toxin genes: *plc*, *cpe*, *becA/B-Beta2*, *cpb*, *etx*, and *itx*. In terms of genes present in bacteris isolated, 19 of the entire *E. coli* isolated possessed *blaTEM* gene, while 14 isolates possessed *blaCTX-25*, *blaCTX-M8*, and *blaCTX-M2* as reported by [38]. Similarly, 8 of the EBSL isolates, harbored *blaTEM*, *blaCTX-M-2*, *blaCTX-M-8* *blaCTX-M-25*, All had *blaCTX-M-1* and *blaCTX-M-9* [35].

Altogether, only (2/23) 9% studies reported the detection and identification of antibiotic residues directly from HWW [28, 49], these residues include, amoxicillin,

chloramphenicol ceftriaxone, azithromycin, ciprofloxacin, clarithromycin, erythromycin, norfloxacin, ofloxacin, oxytetracycline, sulfamethazine, sulfadoxine, sulfamethazine, sulfamethoxazole, tetracycline, thiamphenicol, trimethoprimria.

Meta-analyses of resistant bacteria and resistance genes

Meta-analysis on the resistant bacteria was conducted for bacteria reported by two or more papers. These resistant bacteria were *E. coli*, *K. pneumoniae*, *P. aeruginosa*, *Enterobacter cloacae*, *S. epidermis*, *S. aureus*, and *B. cereus* (Table S5–S11). Even though (9/23) 39.1% of studies reported the isolation and detection of *E. coli*, only 44.4% were eligible for the meta-analysis. The ineligible studies [32, 35, 41, 54], and [38] were not included because for some, the total isolates were not provided in both the paper and supplementary materials, while for others, the total number of isolates was the same as the number of *E. coli* (Table S5).

Similarly, (6/23) 26.1% of studies reported the identification of *K. pneumoniae*. However, only (4/6) 66.7% were eligible for the meta-analysis [43, 46, 48] and [47]. Ineligible studies [54] and [32], were excluded because the total number of isolates was not provided (Table S6).

Altogether, 50% (2/4) of studies that reported resistant *P. aeruginosa* were included in the meta-analysis [36] and [33], while the remaining studies [54] and [32] were excluded because full data on the total number of *P. aeruginosa* and number of *P. aeruginosa* was not included (Table S7). Studies included in the meta-analysis, reporting on *Enterobacter cloacae* (2/3) 66.7% [43] and [37], *S. epidermis* (2/2) 100% [30] and [40], *S. aureus* (2/2) 100% [33] and [40], and *Bacillus cereus* (2/2) 100% [33] and [55]. One of the studies on *Enterobacter cloacae* [32] was excluded because number of *cloacae* was not indicated (Table S8–S11).

The pooled prevalence of *E. coli* in the ($n = 4$) studies was 42.6% (95% CI: 26.7%–60.3%) (Figure S2), *K. pneumoniae* ($n = 4$) 32.1% (95% CI: 28.8%–36.5%) (Figure S4), *P. aeruginosa* ($n = 2$) 23.7% (95% CI = 8.0%–52.8%) (Figure S5), *Enterobacter cloacae* ($n = 2$) 2.9% (95% CI = 0.6%–12.4%) (Figure S6), *S. epidermis* ($n = 2$) 19.1% (95% CI = 2.3%–70.6%) (Figure S7), *S. aureus* ($n = 2$) 19.5% (95% CI = 0.8%–88.2%) (Figure S8), and *B. cereus* ($n = 2$) 18.2% (95% CI = 6.9%–39.8%) (Figure S9). Table 2 summarizes the pool prevalence of the resistant bacteria isolated from HWW among the studies.

Like the resistant bacteria, ARGs reported in two or more reviewed studies were used for the meta-analyses. These 19 ARGs met the criteria for inclusion: *blaTEM*, *blaOXA-48*, *blaSHV*, *mecA*, *blaCMY-1*, *blaCTX-M-1*, *blaCTX-M-15*, *blaCTX-M-25*, *blaCTX-M-8*, *blaCTX-M-9*, *blaDIM-1*, *blaIMP*, *blaNDM*, *blaOXA-1*,

Table 2 Summary of the pool prevalence of isolated resistant bacteria from HWW included in the meta-analysis

Resistant bacteria	No. of papers	No. of bacteria isolated	Pooled prevalence (%)	I ² (%)	p-value
<i>E. coli</i>	4	308	42.6	94.37	< 0.001
<i>K. pneumoniae</i>	4	250	32.1	96.49	< 0.001
<i>P. aeruginosa</i>	2	10	23.7	67.72	0.078
<i>Enterobacter cloacae</i>	2	6	2.9	52.97	0.145
<i>S. epidermis</i>	2	29	19.1	94.87	< 0.001
<i>S. aureus</i>	2	45	19.5	95.33	< 0.001
<i>B. cereus</i>	2	12	18.2	68.86	0.073

NB: The p-value associated with the pooled prevalence indicates whether the estimated prevalence is significantly different from zero at the 95% confidence level

A p-value ≤ 0.05 suggests that the pooled prevalence is statistically significant

blaOXA- 58, blaVIM, Sul- 1, TetA, and TetB (Table S11–S29). However, due to incompleteness of data regarding total number of isolates and number of isolates harbouring a particular gene in some studies, some were further excluded (i.e. *blaCTX-M- 15, blaDIM- 1, blaIMP, blaNDM, blaOXA- 58, and blaVIM*).

Out of the 13 ARGs eligible for meta-analysis, some studies were excluded. Only (2/3) of studies reporting the presence of *blaOXA- 48* were used for the meta-analysis [47] and [46]. Similarly, another gene with only (2/3) studies used for meta-analysis was *mecA* [30] and [31]. The exclusion of these studies is due to unavailability of either complete data on total isolates or number of isolates harboring such genes.

The pooled prevalences of the ARGs were *blaTEM* ($n = 5$) 76.0% (95% CI = 64.6%–84.6%) (Figure S11), *blaOXA- 48* ($n = 2$) 12.0% (95% CI = 5.8%–23.1%) (Figure S12), *blaSHV* ($n = 3$) 59.3% (95% CI = 19.5%–89.8%) (Figure S14), *mecA* ($n = 2$) 32.1% (95% CI = 14.2%–57.4%) (Figure S15), *blaCMY- 1* ($n = 2$) 17.7% (95% CI = 8.1%–34.4%) (Figure S16), *blaCTX-M- 1* ($n = 2$) 97.2% (95% CI = 82.8%–99.6%) (Figure S17), *blaCTX-M- 25* ($n = 2$) 61.0% (95% CI = 44.4%–75.4%) (Figure S18), *blaCTX-M- 8* ($n = 2$) 97.2% (95% CI = 82.8%–99.6%) (Figure S19), *blaCTX-M- 9* ($n = 2$) 97.2% (95% CI = 82.8%–99%) (Figure S20), *blaOXA- 1* ($n = 2$) 45.7% (95% CI = 7.4%–89.9%) (Figure S21), *sul- 1* ($n = 2$) 12.8% (95% CI = 3.2%–39.5%) (Figure S22), *Tet A* ($n = 2$) 69.1% (95% CI = 7.6%–98.4%) (Figure S23), and *Tet B* ($n = 2$) 30.8% (95% CI = 12.0%–59.2%) (Figure S24). Table 3 summarises the ARG pooled prevalences.

Discussion

The objective of this systematic review and meta-analysis was to describe the status of antibacterial resistance comprehensively in HWW in West Africa, regarding the presence of resistant bacteria, resistance genes, and detection of antibiotic residues. Although the antibiotic resistance crisis is at its highest in the region [56],

Table 3 Summary of the pooled prevalence of ARGs included in the meta-analysis

ARGs	No. of papers	No. of isolates	Pooled prevalence (%)	I ² (%)	p-value
<i>blaTEM</i>	5	98	76.0	33.65	0.197
<i>blaOXA- 48</i>	2	7	12.0	0	0.496
<i>blaSHV</i>	3	43	89.6	89.65	< 0.001
<i>mecA</i>	2	13	32.1	57.49	0.125
<i>blaCMY- 1</i>	2	6	17.7	0	0.359
<i>blaCTX-M- 1</i>	2	36	97.2	0	0.740
<i>blaCTX-M- 25</i>	2	22	61.0	0	0.629
<i>blaCTX-M- 8</i>	2	36	97.2	0	0.740
<i>blaCTX-M- 9</i>	2	36	97.2	0	0.740
<i>blaOXA- 1</i>	2	24	45.7	77.48	0.035
<i>sul- 1</i>	2	2	12.8	0	0.699
<i>Tet A</i>	2	9	69.1	75.07	0.045
<i>Tet B</i>	2	4	30.8	0	0.853

NB: The p-value associated with the pooled prevalence indicates whether the estimated prevalence is significantly different from zero at the 95% confidence level

A p-value ≤ 0.05 suggests that the pooled prevalence is statistically significant

fundamental work on antibacterial resistance prevalence in HWW remains scarce, with only 23 eligible articles published between 1990 and 2024. This demonstrates a research gap, which encompasses a larger problem of poor monitoring and lack of proper structures of mitigating ABR threats in HWW. The few studies [4] that were excluded were due inability to get the full articles. This represents approximately 13.3% of the total studies reviewed, which may introduce a limitation by potentially excluding relevant findings. The missing data could impact the comprehensiveness of our analysis, particularly if these studies contained unique insights or region-specific trends. However, the remaining articles provide a broad and representative overview of the topic. Additionally, most of the eligible studies emanated from Nigeria,

while just a few were from Ghana, Benin, and Burkina Faso may either suggest presence of available funding or a high interest in HWW-related antibiotic resistance in that country. Additionally, that most of the sampling conducted in HWWTPs at medical centres and teaching hospitals is very laudable as most of these centres are hotspots for serious health related cases.

In the included studies, culture-dependent techniques, PCR, and metagenomic analysis were used in detection and analysis. The culture-based methods, including use of selective media, biochemical tests, and antibiotic susceptibility tests, were most frequently used, despite their drawbacks, such as inability to isolate non-culturable bacteria and detect new resistance genes. Bacterial PCR and whole-genome sequencing made the detection of resistance genes such as *blaTEM*, *blaCTX-M*, and *blaSHV* more effective. However, metagenomics, which is a more comprehensive approach to identifying the bacteria and the low-density resistance genes, was used in only two of the 23 studies reviewed. This underscores the need to increase the application of metagenomics in West Africa to better understand the looming antibiotic resistance profiles and the resistome of HWW in the region.

The high prevalence of *Escherichia coli*, *Klebsiella pneumoniae*, and *Pseudomonas aeruginosa* in HWW is a public health threat due to their potential to harbour and disseminate antibiotic resistance genes, increasing the risk of treatment failures in clinical settings. These pathogens can persist in the environment, contaminate water sources, and facilitate the spread of multidrug-resistant infections, posing serious challenges to infection control and public health management. These bacteria can cause a range of nosocomial infections including bloodstream, pneumonia and urinary tract infections and most of these infections are often resistant to multiple drugs. For example, *E. coli* is associated with severe diseases including septicemia and urinary tract infections and produces just a low virulence [21] while *K. pneumoniae* is related to a high infection density acquired in hospitals with appreciable rates of morbidity and mortality [57]. Along the same line, *P. aeruginosa* is the common cause of bacteraemia and sepsis in the hospital setting, especially in immunocompromised patients, and is innately resistant to multiple antibiotics making treatment challenging [58]. The pooled prevalence of *E. coli* in HWW 42.6% (95% CI: 26.7%–60.3%) is quite high compared to a HWW in Switzerland (34.1%) [59], but lower than a study conducted in Algeria in a HWW (89.6%) [60]. In terms of different reservoirs, the prevalence is higher compared to that in Ethiopian animal food 15% (95% CI = 13%–17%) [61], and lower in a swimming pool in Bangladesh (33.3%) [62]. This varying prevalence of *E. coli* across

different regions and reservoirs stems from conditions or source of such reservoirs, methods used in detection, as well as the level of treatments of HWW in the hospitals.

Research has found unequal amounts of microbial contamination in drinking water sources in Ghana. According to [63], 13.3% packaged drinking water samples were contaminated with *Escherichia coli* which denoted the faecal contamination and health risks. Like so, [64] found *E. coli* and *Pseudomonas aeruginosa* in sachet packaged drinking water with microbial loads well beyond recommended safety levels. The study went on to identify *Enterobacter aerogenes*, *Klebsiella spp.* and *Proteus vulgaris*, in addition to poor water quality management.

Untreated or inadequately treated HWW discharge is a major contributor to the contamination from ARes, ARGs, and ARBs. As discussed by [65], the risk of pathogenic bacteria, ARes, or multidrug resistant organism contaminating drinking water supplies in the presence of HWW is high. These results underscore the importance of developing better discharge from HWW services and monitoring drinking water sources routinely for microbial contamination to protect public health.

The prevalence of *blaTEM*, *blaOXA-48*, *blaSHV*, and *mecA* were 29%, 18%, 18%, and 18%, respectively. The presence of *blaTEM* gene in pathogen or HWW, depicts the high possibility or presence of beta-lactamase enzymes conferring resistance to penicillin [66]. Similarly, *blaOXA-48* gene found in several reservoirs including HWW codes for carbapenemase enzymes that render carbapenems ineffective, important drugs used in fighting multidrug-resistant infections [67]. The *blaSHV* gene encodes for beta-lactamase that display resistance to several beta-lactam antibiotics including penicillin and cephalosporins [68]. Finally, the *mecA* gene detected is responsible for methicillin resistant in *S. aureus*, thus increasing the spread of MRSA infection [69]. The pooled prevalence of *blaTEM* 76.0% (95% CI = 64.6%–84.6%) in HWW is higher than that of an urban wastewater effluent in South Africa (56.4%) [70], global wastewater 49.88% (95% CI, 35.01%–64.76%) [71], and Indonesia HWW (0.4%). The higher prevalence of *blaTEM* compared to the above countries and region, shows that, West African HWW is highly polluted with pathogens harbouring the gene or they are highly concentrated in the HWW and thus, requires an efficient and effective treatment regimen for public health safety and to prevent further gene transfer in the HWW.

The few studies (about 9%) that worked on antibiotic residue shows great limitations in the studies conducted in West Africa. This could be from lack of facilities or equipment such as HPLC, LC-MS which are useful in elucidating the presence and concentrations of antibiotic residues in HWW [72–74]. According to literature,

a better understanding of resistance transfer in wastewater comes about from the knowledge in the presence of antibiotic residue, antibiotic ARGs, and the presence of antibiotic resistant and non-resistant bacteria [75, 76]. By this logic, conducting ABR in HWW considering all these three main components will generate a comprehensive data to elucidate the mechanisms or nature of resistance transfer.

The high prevalence of resistant bacteria such as *E. coli* and *P. aeruginosa* in HWW and within drinking water sources throughout most of West Africa establishes a clear need for effective measures to preventing pathogen exposure. This is one important strategy to adopt, which is that staff handling HWW (and its treatment) should do so while wearing the appropriate personal protective equipment. Moreover, HWW should be properly and effectively treated prior to discharge into the nearby water bodies to reduce the risks of contamination.

Moreover, HWW treatment and patient facilities should be physically separated to minimize risk of transmission. In addition, hospital management should impose strict control on quality assurance policies to see to it that the levels of resistant genes, antibiotic residues and bacteria before and after treatment remain at safe standard. If not observed, it might lead to biotic contamination of the water bodies under use for mankind for domestic, agricultural and industrial purposes, thereby raising the risk of human exposure to antibiotic resistant pathogens.

One major strength of this systematic review is that it is the first to be conducted on ARGs, ARB, and antibiotic residues in HWW systems in West Africa, providing robust insights on antimicrobial resistance in an understudied antibiotic-resistance hotspot in the region. However, only the existing data were analysed for the purposes of this research. For example, some articles could not be incorporated because their full texts were not accessible. Also, some of the cross-sectional studies were omitted from the meta-analysis component of the study, owing to missing data, which might have impacted the overall prevalence. The disparities in the methods of detection and identification of the ARB and ARGs, along with the heterogeneity of sampling strategies, may have introduced variations in the type of bacteria and genes detected in the outcome underlying the quantification. Another drawback is the scarcity of information about antibiotic residues in HWW, which inhibit proper evaluation of transmission patterns. As a result, meta-analysis could not be done on the available antibiotic residues data.

Challenges in hospital wastewater management and antibiotic resistance in West Africa

In West Africa, the presence of antibiotic-resistant bacteria like *Escherichia coli* and *Pseudomonas aeruginosa* in

HWW raises important public health and environmental issues. The inadequate treatment of hospital effluents in the region is one of the major challenges because resistant bacteria and ARes get into other sources of water such as reservoirs used for irrigation purposes [77]. For instance, many healthcare facilities lack adequate wastewater treatment infrastructure causing effluents, which are either untreated or partially treated to be discharged to rivers and groundwater [78]. In addition, overuse and misuse of antibiotics in hospitals feeds the buildup of resistant strains in the wastewater, complicating efforts to control the rise of antimicrobial resistance (AMR).

Another challenge is that there is no regular monitoring and surveillance of HWW [79]. In many hospitals, there are no protocols in place to test microbial loads and resistance patterns before wastewater is discharged [79]. By not monitoring this gap, the resistant pathogens continue to spread into the environment without intervention. Additionally, the persistence of bacterial contamination in hospital water systems is influenced by inconsistent disinfection practices. However, in some facilities, water disinfection is not performed routinely, which exposes them to nosocomial infection and the contamination of seemingly nearby water sources. There is also a further concern around the limited awareness that healthcare workers have regarding the risk of HWW contamination [80]. Often, doctors and hospital staff do not get routinely informed about the levels of microbial contamination so they cannot take preventative measures to limit exposure.

Recommendations for improving hospital wastewater surveillance and treatment

To tackle the problem of HWW contamination, improved surveillance and wastewater treatment strategies need to be practised. All hospitals should develop standardized testing protocols to detect the levels of bacterial contamination, antibiotic residues and resistance genes in wastewater before and immediately following the treatment. In addition, the advanced wastewater treatment technologies such as membrane filtration, ozonation, or electrochemical disinfection could reduce very substantially the loads of microorganisms before effluents are discharged to the water bodies.

HWW treatment is also important to stop the increase of resistant bacteria caused by patients returning to hospitals if they have a drug treatment. Enforcing strict guidelines for antibiotic prescription, promoting the use of antibiotics only for necessary situations, and promotion of alternative antibiotics that are not broad spectrum are ways by which this can be done. Further efforts to AMR control will include training health care professionals of rational use antibiotic and risk of HWW contamination.

Additionally, hospital water systems in the hospital ought to be regularly disinfected to prevent persistent or spread of bacteria. Establishment of a standardized schedule of disinfection in facilities and physical separation of patient care areas from HWW treatment plants is recommended to reduce exposure risk. In addition, governments must also enforce the strict environmental regulations to compel hospitals to follow the wastewater treatment criteria before the discharging of effluent.

Conclusions

The study highlights a desire to continue closely tracking HWW in West Africa to safeguard the health of patients and others in and around hospitals. *E. coli*, *K. pneumoniae*, and *P. aeruginosa* as well as the resistance genes *blaTEM*, *blaOXA-48*, *blaSHV*, and *mecA* were identified to point to heightened public health concerns concerning the discharge of the resistant organisms into the nearby water bodies. Hence, the treatment procedures require reconsideration and enhancement of the HWW treatment plans to eliminate resistant bacteria, genes, and antibiotics. In turn, it is necessary to expand the surveillance efforts concerning antibiotic residue if there is a desire to build a vast set of data that would allow managing antibiotic residue levels and the corresponding effects on orientations for management practices and the formation of public health policies.

Abbreviations

AR	Antibiotic Resistance
ABR	Antimicrobial Resistance
ARB	Antibiotic-Resistant Bacteria
ARGs	Antibiotic Resistance Genes
ARes	Antibiotic Residues
HGT	Horizontal Gene Transfer
HWW	Hospital Wastewater
PRISMA	Preferred Reporting Items for Systematic Reviews and Meta-Analyses
NOS	Newcastle Ottawa Scale
HWWTP	Hospital Wastewater Treatment Plant
CI	Confidence Interval

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12889-025-22513-w>.

Supplementary Material 1

Acknowledgements

Not applicable.

Authors' contributions

P.H and E.S.D. conceptualize the idea, P.H and E.S.D. designed the methodology of the review, while software usage was done by P.H and E.S.D., All authors were involved in the validation process. Formal analysis was performed by P.H and E.S.D. Data curation was done by P.H and E.S.D., writing—original draft preparation was by P.H., writing—review and editing was performed by P.H, E.S.D, and F.C.N.K., visualization was P.H., funding acquisition was by E.S.D. All authors have read and agreed to the published version of the manuscript."

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This systematic review was supported by the Fogarty International Center of the National Institutes of Health, USA, through the Research and Capacity Building in Antimicrobial Resistance in West Africa (RECABAW) Training Program hosted at the Department of Medical Microbiology, University of Ghana Medical School (Award Number: D43 TW012487). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Data availability

Not applicable, however supplementary data is available.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Received: 12 December 2024 Accepted: 26 March 2025

Published online: 11 April 2025

References

- Huemer M, Mairpady Shambat S, Brugger SD, Zinkernagel AS. Antibiotic resistance and persistence—Implications for human health and treatment perspectives. *EMBO Rep.* 2020;21(12). Available from: <https://www.embopress.org/doi/10.15252/embr.202051034>
- Naghavi M, Vollset SE, Ikuta KS, Swetschinski LR, Gray AP, Wool EE, et al. Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050. *The Lancet.* 2024;404(10459):1199–226. Available from: [https://doi.org/10.1016/S0140-6736\(24\)01867-1](https://doi.org/10.1016/S0140-6736(24)01867-1)
- O'Neill J. Tackling drug-resistant infections globally. Vol. 7, *Archives of Pharmacy Practice.* 2016. 110 p.
- Poudel AN, Zhu S, Cooper N, Little P, Tarrant C, Hickman M, et al. The economic burden of antibiotic resistance: A systematic review and meta-analysis. Karunasagar I, editor. *PLoS One.* 2023;18(5):e0285170. Available from: <https://dx.plos.org/10.1371/journal.pone.0285170>
- Otiaku E, Fenny AP, Labi AK, Ofori AO, Kurtzhals JAL, Enemark U. Attributable Patient Cost of Antimicrobial Resistance: A Prospective Parallel Cohort Study in Two Public Teaching Hospitals in Ghana. *Pharmacoecon Open.* 2023;7(2):257–71. Available from: <https://doi.org/10.1007/s41669-022-00385-9>
- Murray CJL, Ikuta KS, Sharara F, Swetschinski L, Robles Aguilar G, Gray A, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. *The Lancet.* 2022;399(10325):629–55. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0140673621027240>
- Harris M, Fasolino T, Ivankovic D, Davis NJ, Brownlee N. Genetic Factors That Contribute to Antibiotic Resistance through Intrinsic and Acquired Bacterial Genes in Urinary Tract Infections. *Microorganisms.* 2023;11(6):1407. Available from: <https://www.mdpi.com/2076-2607/11/6/1407>
- Manyi-Loh C, Mamphweli S, Meyer E, Okoh A. Antibiotic Use in Agriculture and Its Consequential Resistance in Environmental Sources: Potential Public Health Implications. *Molecules.* 2018;23(4):795. Available from: <https://www.mdpi.com/1420-3049/23/4/795>
- Muteeb G, Rehman MT, Shahwan M, Aatif M. Origin of Antibiotics and Antibiotic Resistance, and Their Impacts on Drug Development: A Narrative Review. *Pharmaceuticals.* 2023;16(11):1615. Available from: <https://www.mdpi.com/1424-8247/16/11/1615>
- Pandey S, Doo H, Keum GB, Kim ES, Kwak J, Ryu S, et al. Antibiotic resistance in livestock, environment and humans: One Health perspective. *J*

- Anim Sci Technol. 2024;66(2):266–78. Available from: https://www.ejast.org/archive/view_article?doi=10.5187/jast.2023.e129
11. Lorenzo P, Adriana A, Jessica S, Carles B, Marinella F, Marta L, et al. Antibiotic resistance in urban and hospital wastewaters and their impact on a receiving freshwater ecosystem. *Chemosphere*. 2018;206:70–82. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S004565351830818X>
 12. Zhang Y, Zhao Z, Xu H, Wang L, Liu R, Jia X. Fate of antibiotic resistance genes and bacteria in a coupled water-processing system with wastewater treatment plants and constructed wetlands in coastal eco-industrial parks. *Ecotoxicol Environ Saf*. 2023;252:114606. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0147651323001100>
 13. Zhu S, Yang B, Wang Z, Liu Y. Augmented dissemination of antibiotic resistance elicited by non-antibiotic factors. *Ecotoxicol Environ Saf*. 2023;262:115124. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0147651323006280>
 14. Avershina E, Shapovalova V, Shipulin G. Fighting Antibiotic Resistance in Hospital-Acquired Infections: Current State and Emerging Technologies in Disease Prevention, Diagnostics and Therapy. *Front Microbiol*. 2021;12. Available from: <https://www.frontiersin.org/articles/10.3389/fmicb.2021.707330/full>
 15. Mehanni MM, Gadow SI, Alshammari FA, Modafar Y, Ghanem KZ, El-Tahtawi NF, et al. Antibiotic-resistant bacteria in hospital wastewater treatment plant effluent and the possible consequences of its reuse in agricultural irrigation. *Front Microbiol*. 2023;14. Available from: <https://www.frontiersin.org/articles/10.3389/fmicb.2023.1141383/full>
 16. Barancheshme F, Munir M. Strategies to combat antibiotic resistance in the wastewater treatment plants. *Front Microbiol*. 2018;8. Available from: <https://journal.frontiersin.org/article/10.3389/fmicb.2017.02603/full>
 17. Singh BJ, Chakraborty A, Sehgal R. A systematic review of industrial wastewater management: Evaluating challenges and enablers. *J Environ Manage*. 2023; 348:119230. Available from: <https://www.sciencedirect.com/science/article/pii/S0301479723020182>
 18. Tadesse BT, Ashley EA, Ongarello S, Havumaki J, Wijegoonewardena M, González JJ, et al. antimicrobial resistance in Africa: a systematic review. *BMC Infect Dis*. 2017;17(1):616. Available from: <https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-017-2713-1>
 19. Amin N, Foster T, Shimki NT, Willetts J. Hospital wastewater (HWW) treatment in low- and middle-income countries: A systematic review of microbial treatment efficacy. *Sci Total Environ*. 2024; 921:170994. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0048969724011331>
 20. Carraro E, Bonetta S, Bertino C, Lorenzi E, Bonetta Sa, Gilli G. Hospital effluents management: Chemical, physical, microbiological risks and legislation in different countries. *J Environ Manage*. 2016; 168:185–99. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0301479715303753>
 21. Zhang S, Huang J, Zhao Z, Cao Y, Li B. Hospital wastewater as a reservoir for antibiotic resistance genes: a meta-analysis. *Front Public Health*. *Front Public Health*. 2020;8. Available from: <https://www.frontiersin.org/articles/10.3389/fpubh.2020.574968/full>
 22. Hassoun-Kheir N, Stabholz Y, Kreft JU, de la Cruz R, Romalde JL, Nesme J, et al. Comparison of antibiotic-resistant bacteria and antibiotic resistance genes abundance in hospital and community wastewater: A systematic review. *Science of The Total Environment*. 2020 Nov; 743:140804. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S004896972034328X>
 23. Ebrahimi SM, Dehghanzadeh Reyhani R, Asghari-JafarAbadi M, Fathifar Z. Diversity of antibiotics in hospital and municipal wastewaters and receiving water bodies and removal efficiency by treatment processes: a systematic review protocol. *Environ Evid*. 2020;9(1):19. Available from: <https://environmentalevidencejournal.biomedcentral.com/articles/https://doi.org/10.1186/s13750-020-00201-z>
 24. Evoung Chandja WB, Onanga R, Mbehang Nguema PP, Lendamba RW, Mouanga-Ndzime Y, Mavoungou JF, et al. Emergence of Antibiotic Residues and Antibiotic-Resistant Bacteria in Hospital Wastewater: A Potential Route of Spread to African Streams and Rivers, a Review. *Water (Basel)*. 2024;16(22):3179. Available from: <https://www.mdpi.com/2073-4441/16/22/3179>
 25. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for systematic reviews. *Syst Rev*. 2016;5(1):210. Available from: <http://systematicreviewsjournal.biomedcentral.com/articles/https://doi.org/10.1186/s13643-016-0384-4>
 26. Wells GA, Wells G, Shea B, Shea B, O'Connell D, Peterson J, et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. In 2014. Available from: <https://api.semanticscholar.org/CorpusID:79550924>
 27. Odih EE, Sunmonu GT, Okeke IN, Dalsgaard A. wastewater of a Nigerian hospital. *Microbiol Spectr*. 2022;11(6).
 28. Ajibola AS, Zwiener C. Occurrence and Risk Assessment of Antibiotic Residues in Sewage Sludge of Two Nigerian Hospital Wastewater Treatment Plants. *Water Air Soil Pollut*. 2022;233(10). Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85139181658&doi=10.1007%2Fs11270-022-05875-4&partnerID=40&md5=956057434cb31fd6b80a76275c8f917>
 29. Agboola TD, Nmema EE, Odetoyin BW. Distribution and antibiogram of *Vibrio* species from hospital wastewater in Southwest Nigeria. *Pan Afr Med J*. 2023;45. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85168353355&doi=10.11604%2Fpamj.2023.45.80.35773&partnerID=40&md5=d219b99cbba2b8c98220d9ebcb0c9612>
 30. Adekanmbi AO, Soyoye OF, Adelowo OO. Characterization of methicillin-resistance gene *mecA* in coagulase negative staphylococci (CoNS) recovered from wastewater of two healthcare facilities in Nigeria. *Gene Rep*. 2019;17. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85074147656&doi=10.1016%2Fj.genrep.2019.100541&partnerID=40&md5=32f1909d75cb3a7821d154f585cb27be>
 31. Emoruwa T, Omoya O. Incidence of methicillin-resistant *Staphylococcus aureus* in wastewater and its survival after discharge from two hospitals in Akure, Nigeria NUSANTARA BIOSCIENCE. 2024;16(1):119–29.
 32. Adenike AOO, Ayansina DA. Occurrence of Extended Spectrum Beta Lactamase (ESBL) Producing Gram-Negative Bacteria in Wastewaters from Selected Hospitals in Ibadan, Oyo State, Nigeria. *Trop J Nat Prod Res*. 2022;6(5):826–30. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85135296193&doi=10.26538%2Ftjnp%2Fv6i5.27&partnerID=40&md5=e3ddc96a8810a9de51e5771f7b47a1>
 33. Adelowo OO, Fagade OE, Oke AJ. Prevalence of co-resistance to disinfectants and clinically relevant antibiotics in bacterial isolates from three hospital laboratory wastewaters in Southwestern Nigeria. *World J Microbiol Biotechnol*. 2008;24(9):1993–7. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-48349098946&doi=10.1007%2Fs11274-008-9697-3&partnerID=40&md5=3275c99bcae7de7592ca5aba33d674a1>
 34. Akinola OTOT, Dahunsi SO, Okoh A, Group WHOA, Surveillance I, Resistance A, et al. Molecular characterization and detection of multidrug-resistant gene in bacterial strains in a health care centre located in Iwo, Osun State, Nigeria. *Gene Rep*. 6th ed. 2023;21(1):129–31. Available from: <https://doi.org/10.1016/j.etap.2022.103995>
 35. Adekanmbi AO, Akinpelu MO, Olaposi A V, Oyelade AA. Extended spectrum beta-lactamase encoding gene-fingerprints in multidrug resistant *Escherichia coli* isolated from wastewater and sludge of a hospital treatment plant in Nigeria. *International Journal of Environmental Studies*. 2020;140–50. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85088457100&doi=10.1080%2F0207233.2020.1778271&partnerID=40&md5=5ba11561ec3cc7e279aa80a4bf90308c>
 36. Adekanmbi AO, Adejoba AT, Banjo OA, Saki M. Detection of *sul1* and *sul2* genes in sulfonamide-resistant bacteria (SRB) from sewage, aquaculture sources, animal wastes and hospital wastewater in South-West Nigeria. *Gene Rep*. 2020;20(May):100742. Available from: <https://doi.org/10.1016/j.genrep.2020.100742>
 37. Banjo OA, Adekanmbi AO, Oyelade AA. Occurrence of CTX-M, SHV and TEM β -lactamase genes in Extended Spectrum Beta-Lactamase (ESBL)-producing bacteria recovered from wastewater of a privately-owned hospital in Nigeria and a hand-dug well within its vicinity. *Gene Rep*. 2020;21. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85097078538&doi=10.1016%2Fj.genrep.2020.100970&partnerID=40&md5=7caa66247289c7e0a4d4cbac1978a10d>
 38. Adekanmbi AO, Akinpelu MO, Olaposi AV, Oyelade AA. Diversity of Extended Spectrum Beta-lactamase (ESBL) genes in *Escherichia coli* isolated from wastewater generated by a Sick Bay located in a University Health Care Facility. *Gene Rep*. 2020;20(March):100738. Available from: <https://doi.org/10.1016/j.genrep.2020.100738>
 39. Mtetwa HN, Amoah ID, Kumari S, Bux F, Reddy P. Surveillance of multi-drug-resistant tuberculosis in sub-Saharan Africa through wastewater-based epidemiology. *Heliyon*. 2023;9(8). Available from: [https://www.scopus.com/inward/record.uri?eid=2-s2.0-85165651664&doi=10.1016%](https://www.scopus.com/inward/record.uri?eid=2-s2.0-85165651664&doi=10.1016%2F)

- 2Fj.heliyon.2023.e18302&partnerID=40&md5=f8d18b104af6b3c804d0a47a123d8b02
40. Oladipo AO, Oladipo OG, Bezuidenhout CC. Multi-drug resistance traits of methicillin-resistant Staphylococcus aureus and other Staphylococcal species from clinical and environmental sources. *J Water Health*. 2019;17(6):930–43.
 41. Tettey R, Egyir B, Tettey P, Arko-Mensah J, Ofori Addo S, Owusu-Nyantakyi C, et al. Genomic analysis of multidrug-resistant *Escherichia coli* from Urban Environmental water sources in Accra, Ghana, Provides Insights into public health implications. *PLoS One*. 2024;19(5 May):1–29. Available from: <https://doi.org/10.1371/journal.pone.0301531>
 42. Kawamura T, Prah I, Mahazu S, Ablordey A, Saito R. Types A and F Clostridium perfringens in healthcare wastewater from Ghana. 2023;89(12).
 43. Addae-Nuku DS, Kotey FCN, Dayie NTKD, Osei MM, Tettey EMA, Debrah P, et al. Multidrug-Resistant Bacteria in Hospital Wastewater of the Korle Bu Teaching Hospital in Accra, Ghana. *Environ Health Insights*. 2022;16. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85140308114&doi=10.1177%2F11786302221130613&partnerID=40&md5=9843d21f737908bd987c33eda52ba6a>
 44. Delgado-Blas JF, Valenzuela Agüi C, Marin Rodriguez E, Serna C, Montero N, Saba CKS, et al. Dissemination Routes of Carbapenem and Pan-Aminoglycoside Resistance Mechanisms in Hospital and Urban Wastewater Canalizations of Ghana. *mSystems*. 2022;7(1). Available from: [https://www.scopus.com/inward/record.uri?eid=2-s2.0-85125140011&doi=10.1128%2FmSystems.01019-21&partnerID=40&md5=4715fd2f31807907077983069a4ab9d3](https://www.scopus.com/inward/record.uri?eid=2-s2.0-85125140011&doi=10.1128%2FmSystems.01019-21&partnerID=40&md5=4715fd2f3180790)
 45. Markkanen MA, Haukka K, Pärnänen KMM, Dougnon VT, Bonkoungou IJO, Garba Z, et al. Metagenomic Analysis of the Abundance and Composition of Antibiotic Resistance Genes in Hospital Wastewater in Benin, Burkina Faso, and Finland. *mSphere*. 2023;8(1). Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85148479885&doi=10.1128%2FmSphere.00538-22&partnerID=40&md5=ca460e5d174269ad1827d0f3b603df1f>
 46. Muhigwa M, Sanou S, Kantagba D, Ouangraoua S, Yehouenou CL, Michodigni F, et al. Characterization of extended-spectrum beta-lactamase and carbapenemase genes in bacteria from environment in Burkina Faso. *J Infect Dev Ctries*. 2023;17(12):1714–21. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85183263215&doi=10.3855%2Fjiddc.18116&partnerID=40&md5=9a5314bb39e9120c87bce9df71a0f969>
 47. Kagambèga AB, Dembélé R, Bientz L, M'Zali F, Mayonnove L, Mohamed AH, et al. Detection and Characterization of Carbapenemase-Producing *Escherichia coli* and *Klebsiella pneumoniae* from Hospital Effluents of Ouagadougou, Burkina Faso. *Antibiotics*. 2023;12(10). Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85175308279&doi=10.3390%2Fantibiotics12101494&partnerID=40&md5=c1beb874ed2115a47bd60d3e2e01ad5>
 48. Garba Z, Bonkoungou IOJ, Millogo NO, Natama HM, Vokouma PAP, Bonko M dit A, et al. Wastewater from healthcare centers in Burkina Faso is a source of ESB, AmpC-β-lactamase and carbapenemase-producing *Escherichia coli* and *Klebsiella pneumoniae*. Vol. 23, *BMC Microbiology*. *BioMed Central*; 2023. p. 1–8. Available from: <https://doi.org/10.1186/s12866-023-03108-0>
 49. Ouédraogo GA, Cissé H, Ouédraogo HS, Kaboré B, Traoré R, Traoré Y, et al. Research of Antibiotic Residues and Bacterial Strain's Antibiotic Resistance Profile in the Liquid Effluents Evacuated in Nature by Two CHUs and a Mixed WWTP of Ouagadougou (Burkina Faso). *Infect Drug Resist*. 2023;16(April):2537–47.
 50. Hassoun-Kheir N, Stabholz Y, Krefit JU, de la Cruz R, Romalde JL, Nesme J, et al. Comparison of antibiotic-resistant bacteria and antibiotic resistance genes abundance in hospital and community wastewater: A systematic review. *Science of the Total Environment*. 2020;743. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85088225239&doi=10.1016%2Fj.scitotenv.2020.140804&partnerID=40&md5=dca760317646051cf3afa89ac0a3e6dd>
 51. Mtetwa HN, Amoah ID, Kumari S, Bux F, Reddy P. Wastewater-Based Surveillance of Antibiotic Resistance Genes Associated with Tuberculosis Treatment Regimen in KwaZulu Natal, South Africa. *ANTIBIOTICS-BASEL*. 2021;10(11).
 52. Delgado-Blas JF, Agüi C V, Rodriguez EM, Serna C, Montero N, Saba CKS, et al. Dissemination Routes of Carbapenem and Pan-Aminoglycoside Resistance Mechanisms in Hospital and Urban Wastewater Canalizations of Ghana. *mSystems*. 2022;7(1). Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85125140011&doi=10.1128%2FmSystems.01019-21&partnerID=40&md5=4715fd2f318079077983069a4ab9d3>
 53. Atobatele BO, Akinola OT, Olutona GO. Molecular characterization and detection of multidrug-resistant gene in bacterial strains in a health care centre located in Iwo, Osun State, Nigeria. *Sci Afr*. 2023(21) e01866. Available from: March 2022. <https://doi.org/10.1016/j.sciaf.2023.e01866>.
 54. Adekanmbi AO, Soyoye OF, Adelowo OO. Characterization of methicillin-resistance gene *mecA* in coagulase negative staphylococci (CoNS) recovered from wastewater of two healthcare facilities in Nigeria. *Gene Rep*. 2019;17(October):100541. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S2452014419301839>
 55. Atobatele BO, Akinola OT, Olutona GO. Molecular characterization and detection of multidrug-resistant gene in bacterial strains in a health care centre located in Iwo, Osun State, Nigeria. *Sci Afr*. 2023;21. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85169465759&doi=10.1016%2Fj.sciaf.2023.e01866&partnerID=40&md5=3e5572dafc76d037cd0d564e23a64fc6>
 56. Bernabé KJ, Langendorf C, Ford N, Ronat JB, Murphy RA. Antimicrobial resistance in West Africa: a systematic review and meta-analysis. *Int J Antimicrob Agents*. 2017;50(5):629–39. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0924857917302741>
 57. Li D, Huang X, Rao H, Yu H, Long S, Li Y, et al. *Klebsiella pneumoniae* bacteremia mortality: a systematic review and meta-analysis. *Front Cell Infect Microbiol*. 2023;13. Available from: <https://www.frontiersin.org/articles/10.3389/fcimb.2023.1157010/full>
 58. Reynolds D, Kollef M. The epidemiology and pathogenesis and treatment of *Pseudomonas aeruginosa* infections: an update. *Drugs*. 2021;81(18):2117–31. Available from: <https://link.springer.com/10.1007/s40265-021-01635-6>
 59. Sakkas H, Bozidis P, Iliia A, Mpekoulis G, Papadopoulou C. Antimicrobial Resistance in Bacterial Pathogens and Detection of Carbapenemases in *Klebsiella pneumoniae* Isolates from Hospital Wastewater. *Antibiotics*. 2019;8(3):85. Available from: <https://www.mdpi.com/2079-6382/8/3/85>
 60. Anssour L, Messai Y, Estepa V, Torres C, Bakour R. Characteristics of ciprofloxacin-resistant Enterobacteriaceae isolates recovered from wastewater of an Algerian hospital. *The Journal of Infection in Developing Countries*. 2016;10(07):728–34. Available from: <https://jiddc.org/index.php/journal/article/view/27482804>
 61. Assefa A, Bihon A. A systematic review and meta-analysis of prevalence of *Escherichia coli* in foods of animal origin in Ethiopia. *Heliyon*. 2018;4(8):e00716. Available from: <https://www.sciencedirect.com/science/article/pii/S2405844018310119>
 62. Ashrafun N, Md. AI, Md. AS, Md. JH, Sumaiya BZ, Md. BR, et al. Detection of tetracycline resistant *E. coli* and *Salmonella* spp. in sewage, river, pond and swimming pool in Mymensingh, Bangladesh. *Afr J Microbiol Res*. 2019;13(25):382–7. Available from: <https://academicjournals.org/journal/AJMR/article-abstract/4E8CC3161497>
 63. Ahmed H, Zolfo M, Williams A, Ashubwe-Jalemba J, Tweya H, Adeapena W, et al. Antibiotic-Resistant Bacteria in Drinking Water from the Greater Accra Region, Ghana: A Cross-Sectional Study, December 2021–March 2022. *Int J Environ Res Public Health*. 2022;19(19):12300. Available from: <https://www.mdpi.com/1660-4601/19/19/12300>.
 64. Stoler J, Ahmed H, Asantewa Frimpong, Lady, Bello M. Presence of *Pseudomonas aeruginosa* in coliform-free sachet drinking water in Ghana. *Food Control*. 2015;55:242–7. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0956713515001310>.
 65. Olaoye OA, Onilude AA. Assessment of microbiological quality of sachet-packaged drinking water in Western Nigeria and its public health significance. *Public Health*. 2009;123(11):729–34. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0033350609002704>
 66. Ibrahim M, Algak T, Abbas M, Elamin B. Emergence of bla TEM , bla CTX-M , bla SHV and bla OXA genes in multidrug-resistant Enterobacteriaceae and *Acinetobacter baumannii* in Saudi Arabia. *Exp Ther Med*. 2021;22(6):1450. Available from: <https://www.spandidos-publications.com/10.3892/etm.2021.10885>
 67. Flach CF, Hutinel M, Razavi M, Åhrén C, Larsson DGJ. Monitoring of hospital sewage shows both promise and limitations as an early-warning system for carbapenemase-producing Enterobacteriales in a low-prevalence setting. *Water Res*. 2021;200:117261. Available from: <https://www.sciencedirect.com/science/article/pii/S0043135421004590>

68. Ahmad Hamad P, Khadija KM. Prevalence Of Blatem, Blashv, And Blactx-M Genes Among Esbl-Producing Klebsiella Pneumoniae And Escherichia Coli Isolated From Thalassemia In Erbil, Iraq. *Mediterr J Hematol Infect Dis*. 2019;11(1):E2019041. Available From: <https://www.Mjhid.Org/Index.Php/Mjhid/Article/View/2019.041>
69. Wielders CLC, Fluit AC, Brisse S, Verhoef J, Schmitz FJ. mecA gene is widely disseminated in staphylococcus aureus population. *J Clin Microbiol*. 2002;40(11):3970–5. Available from: <https://journals.asm.org/doi/10.1128/JCM.40.11.3970-3975.2002>
70. Adefisoye MA, Okoh AI. Identification and antimicrobial resistance prevalence of pathogenic Escherichia coli strains from treated wastewater effluents in Eastern Cape, South Africa. *Microbiologypopen*. 2016;5(1):143–51. Available from: <https://onlinelibrary.wiley.com/doi/10.1002/mbo3.319>
71. Zaatout N, Bouras S, Slimani N. Prevalence of extended-spectrum β -lactamase (ESBL)-producing Enterobacteriaceae in wastewater: a systematic review and meta-analysis. *J Water Health*. 2021;19(5):705–23. Available from: <https://iwaponline.com/jwh/article/19/5/705/83869/Prevalence-of-extended-spectrum-lactamase-ESBL>
72. Aa J, Wa J, Jms J. Hplc Method For The Determination Of Some Antibiotic Residues In Different Hospitals Wastewater In Baghdad City, Iraq. *Chem-chemtech*. 2024;67(6):21–8 Available From: <https://Ctj-lsuct.Ru/Article/View/5565>.
73. Opris O, Soran ML, Coman V, Copaciu F, Ristoiu D. Determination of some frequently used antibiotics in waste waters using solid phase extraction followed by high performance liquid chromatography with diode array and mass spectrometry detection. *Open Chem*. 2013;11(8):1343–51. Available from: <https://www.degruyter.com/document/doi/10.2478/s11532-013-0263-y/html>
74. Kumar Mehata A, Lakshmi Suseela MN, Gokul P, Kumar Malik A, Kasi Viswanadh M, Singh C, et al. Fast and highly efficient liquid chromatographic methods for qualification and quantification of antibiotic residues from environmental waste. *Microchem J*. 2022;179:107573. Available from: <https://www.sciencedirect.com/science/article/pii/S0026265X22004015>
75. Mutuku C, Gazdag Z, Melegh S. Occurrence of antibiotics and bacterial resistance genes in wastewater: resistance mechanisms and antimicrobial resistance control approaches. *World J Microbiol Biotechnol*. 2022;38(9):152. Available from: <https://link.springer.com/10.1007/s11274-022-03334-0>
76. Uluseker C, Kaster KM, Thorsen K, Basiry D, Shobana S, Jain M, et al. A review on occurrence and spread of antibiotic resistance in wastewaters and in wastewater treatment plants: mechanisms and perspectives. *Front Microbiol*. 2021 ;12. Available from:<https://www.frontiersin.org/articles/10.3389/fmicb.2021.717809/full>
77. Barathe P, Kaur K, Reddy S, Shriram V, Kumar V. Antibiotic pollution and associated antimicrobial resistance in the environment. *Journal of Hazardous Materials Letters*. 2024;5:100105. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S2666911024000042>
78. Khan MT, Shah IA, Ihsanullah I, Naushad Mu, Ali S, Shah SHA, et al. Hospital wastewater as a source of environmental contamination: An overview of management practices, environmental risks, and treatment processes. *Journal of Water Process Engineering*. 2021 ;41:101990. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S2214714421000775>
79. Omohwovo EJ. Wastewater Management in Africa: Challenges and Recommendations. *Environ Health Insights*. 2024;18. Available from:<https://journals.sagepub.com/doi/10.1177/11786302241289681>
80. Letho Z, Yangdon T, Lhamo C, Limbu CB, Yoezer S, Jamtsho T, et al. Awareness and practice of medical waste management among healthcare providers in National Referral Hospital. Ashkenazi I, editor. *PLoS One*. 2021;16(1):e0243817. Available from: <https://dx.plos.org/10.1371/journal.pone.0243817>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.